Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fruquintinib + Capecitabine as Adjuvant Extended Therapy in Liver-Only Metastatic Colorectal Cancer
NCT07885384Phase 3Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Oct 2026
- Primary completion
- Apr 2029
01
Overview
A Phase 3 trial of fruquintinib in colorectal cancer (CRC), sponsored by West China Hospital of Sichuan University. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
fruquintinib
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT07885384.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07885384.